ISRCTN04483921进行中（未招募）2 期
Dose EscaLation to Intraprostatic tumour Nodules in localisEd prostATE cancer: A phase II study examining the toxicity and feasibility of a dose escalated boost to a magnetic resonance imaging identified tumour nodule or nodules in localised prostate cancer
Institute for Cancer Research (UK)0 个研究点目标入组 265 人开始时间: 2011年8月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 265
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36150450/ (added 29/09/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Age more than or equal to 18 years
- •2. Histologically confirmed adenocarcinoma of the prostate
- •3. National Collaborative Cancer Network+ (NCCN) risk groups intermediate or high risk localised prostate cancer
- •4. Normal blood count [haemoglobin (Hb) > 11g/dl, white blood cell (WBC) > 4000/mm³, platelets > 100,000/mm³]
- •5. World Health Organisation (WHO) performance status 0 or 1
- •6. Life expectancy of 10 years or more
- •7. Written informed consent
- •8. Patients must be prepared to attend follow-up
- •9. For template biopsy sub-study must be considered fit for general / spinal anaesthetic; Target Gender: Male ; Lower Age Limit 18 no age limit or unit specified
排除标准
- •1. Prior radiotherapy to the prostate or pelvis
- •2. Bilateral hip replacement
- •3. Prior hormone therapy
- •4. Radical prostatectomy
- •5. Lymph Node Risk > 30%
- •6. National Collaborative Cancer Network+ (NCCN) Favourable Risk Group
- •7. Evidence of seminal vesicle invasion, nodal or metastatic disease
- •8. Any previous invasive cancer in the past 5 years, with the exception of non-melanoma skin cancer
- •9. Patients with medical contraindication to magnetic resonance imaging (MRI) scanning
研究者
相似试验
进行中（未招募）
不适用
Examining the impacts of pathologists using the assistance of computer technology (artificial intelligence software) on the diagnosis of prostate cancer biopsiesMalignant neoplasm of prostateProstate cancerCancerISRCTN91685765niversity of Oxford1,500
招募中
不适用
Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia;Benign Prostatic HyperplasiaNCT06601179EDAP TMS S.A.100
招募中
不适用
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 FractionsProstate CancerNCT06638541Royal Marsden NHS Foundation Trust54
已完成
不适用
Prostate and urethral dosimetry in high dose rate brachytherapy for prostate cancerMeasument of prostatic tissue and urethral doses in HDR brachytherapy for prostate cancerJPRN-UMIN000005123Kawasaki Medical School10
已完成
1 期
Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate CancerProstate CancerNCT00129025Alberta Health services35